Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -2.78
- Piotroski Score 1.00
- Grade Buy
- Symbol (ENTO)
- Company Entero Therapeutics, Inc.
- Price $0.45
- Changes Percentage (9.23%)
- Change $0.04
- Day Low $0.39
- Day High $0.46
- Year High $14.51
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides; biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; capeserod, a selective 5-HT4 receptor partial agonist to treat gastroparesis; and niclosamide, an oral small molecule with anti-inflammatory properties for patients with inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease. It is also developing CypCel, a disease management tool for monitoring the intestinal health of recovering celiac disease patients. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/26/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.00
- Trailing P/E Ratio N/A
- Forward P/E Ratio N/A
- P/E Growth N/A
- Net Income $-15,794,983
Income Statement
Quarterly
Annual
Latest News of ENTO
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
A's Move to Sacramento Unpopular With Dodgers' Free Agent: Report
The Oakland A's are relocating to a Triple-A ballpark in Sacramento in 2025, potentially affecting free agent talks. Manager Mark Kotsay mentioned difficulties in negotiations with Walker Buehler, hig...
By Newsweek | 21 hours ago -
The Sacramento Kings hope their first real rest is the cure for their uneven start
The Sacramento Kings navigated a grueling early-season schedule with multiple games in a short span. Despite a slightly disappointing record, the team is regrouping with key players returning from inj...
By The New York Times | 1 day ago -
Oil prices edge up on geopolitical tensions; higher-than-expected US inventories cap gains
By Siyi LiuSINGAPORE (Reuters) - Oil prices rose marginally on Thursday as geopolitical concerns over escalating tensions between Russia and Ukraine countered the impact from a bigger-than-expecte...
By Reuters | 2 days ago
